Drug firm agrees to publish all results of anti-depressant trials

A pharmaceutical company accused of suppressing negative studies
of its anti-depressant drugs has agreed to publish all information
from its clinical trials, writes Craig
Kenny.

GlaxoSmithKline also agreed to pay $2.5m in a settlement with New
York State Attorney General Eliot Spitzer.

GSK had already agreed to publish information about its drug
Seroxat, following allegations that studies suggesting links with
suicidal thoughts in children were suppressed. It will now publish
all its drug trial data since December 2000 on the internet.

GSK insisted the charges were unfounded but said it had settled the
case to avoid the cost of protracted litigation.